Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Venous Thromboembolism 2Venous Thrombosis 1Vascular Diseases 1Urogenital Neoplasms 1Thromboembolism 1Prostatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1Intestinal Neoplasms 1Hemostatic Disorders 1Digestive System Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 8dacetuzumab 5blinatumomab 5ibrutinib 3Cyclophosphamide 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Vincristine 2Prednisone 2Lutetium 2Ifosfamide 2Everolimus 2Etoposide 2Doxorubicin 2Carboplatin 2venetoclax 1sepantronium 1pomalidomide 1obinutuzumab 1fludarabine 1ficlatuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1amonafide 1Vorinostat 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphatic Diseases × Tinzaparin × Clear all
NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Digestive System Neoplasms, Intestinal Neoplasms, Leukemia, Lung Neoplasms, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Prostatic Neoplasms, Thromboembolism, Urogenital Neoplasms, Vascular Diseases, Colorectal Neoplasms, Hemostatic Disorders, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡